{"date":"2025-01-31","count":1,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6580-2025-01-31-2127-mx77lc","company_id":"6580","company":"台睿","market":"興櫃","industry":"生技醫療","date":"2025-01-31","time":"21:27:19","subject":"公告本公司開發中抗癌口服新藥CVM-1118獲美國FDA授予孤兒藥資格用於胰腺神經內分泌腫瘤(PNETs)的治療。","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：台睿（6580），2025-01-31 21:27，「公告本公司開發中抗癌口服新藥CVM-1118獲美國FDA授予孤兒藥資格用於胰腺神經內分泌腫瘤(PNETs)的治療。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}